Quercetin prevent airway epithelial remodeling and promote lung health in OPD

槲皮素可预防 OPD 患者气道上皮重塑并促进肺部健康

基本信息

项目摘要

PROJECT SUMMARY Patients with chronic obstructive pulmonary disease often show airway epithelial remodeling including basal cell hyperplasia, and goblet cell and squamous cell metaplasia. Such pathologic changes profoundly affect the outcome of respiratory infection as airway epithelium plays a crucial role in defining the innate and adaptive immunity in the lungs. Airway basal cells are the specialized stem cells and regenerate functional mucociliary- differentiated airway epithelium upon injury. The fact that COPD patients show airway epithelial remodeling indicate dysregulated repair mechanisms in airway basal cells. Our research suggests that quercetin, a natural polyphenol reverses airway epithelial remodeling in a mouse model of COPD. Our preliminary studies indicate that quercetin reprograms dysregulated repair pathways in COPD basal cells leading to regeneration of normal airway epithelium. We conducted transcriptomic analysis of airway basal cells from healthy non-smokers and COPD subjects and COPD basal cells treated with quercetin. Results from this microarray indicated dysregulation of genes involved in tissue development and epithelial differentiation in COPD cells. Intriguingly, the topmost differentially regulated genes in both these pathways are genes involved in lung morphogenesis HOXA1 and HOXB2. In normal basal cells, HOXA1 is highly expressed in basal cells, while HOXB2 expression increased at two weeks of culturing and correlated with polarization of cells, a prerequisite step in differentiation. COPD basal cells showed significantly reduced expression of both HOXA1 and HOXB2 and quercetin treatment increased expression of both genes. Based on these observations, we will examine a novel hypotheses that quercetin via modulation of HOXA1 and HOXB2 corrects the dysregulated repair mechanisms, thus improving immune responses to respiratory infections and lung function in COPD. In Specific Aim 1, we will determine the role of HOXA1 and HOXB2 in the regeneration of airway epithelium, and whether quercetin corrects the dysregulated repair mechanism in COPD by modulation of these HOX genes. In Specific Aim 2, we will examine the molecular mechanisms by which quercetin-induced HOXA1 and HOXB2 participates in the regeneration of airway epithelium. In Specific Aim 3, we will examine whether quercetin-induced HOXA1 and HOXB2 participate in limiting exaggerated innate immune responses to rhinovirus infection and prevent progression of lung disease in COPD. Finally, we will confirm whether quercetin treatment reduces airway epithelial remodeling in COPD patients and correlate with the expression of HOXA1 and HOXB2. Completion of these studies will provide important insight into airway epithelial regeneration and the mechanisms by which quercetin reduces airway epithelial remodeling in COPD.
项目摘要 慢性阻塞性肺疾病患者常表现为气道上皮重塑,包括基底细胞 增生、杯状细胞和鳞状细胞化生。这种病理变化深刻地影响着 呼吸道感染的结果,因为气道上皮在定义先天性和适应性 肺部的免疫力气道基底细胞是特化的干细胞,并再生功能性粘膜纤毛。 分化的气道上皮细胞。COPD患者气道上皮重塑 表明气道基底细胞的修复机制失调。我们的研究表明,槲皮素,一种天然的 多酚逆转COPD小鼠模型气道上皮重塑。我们的初步研究表明 槲皮素重新编程COPD基底细胞中失调的修复途径,导致正常细胞的再生, 气道上皮我们对健康非吸烟者的气道基底细胞进行了转录组学分析, COPD受试者和用槲皮素处理的COPD基底细胞。微阵列的结果表明 COPD细胞中参与组织发育和上皮分化的基因失调。有趣的是, 在这两条通路中最高的差异调节基因是与肺形态发生有关的基因 HOXA 1和HOXB 2。在正常的基底细胞中,HOXA 1在基底细胞中高表达,而HOXB 2在基底细胞中高表达。 在培养两周时增加,并与细胞极化相关,这是分化的先决条件。 COPD基底细胞显示HOXA 1和HOXB 2的表达和槲皮素处理显著降低, 这两种基因的表达都增加了。基于这些观察,我们将研究一个新的假设, 槲皮素通过调节HOXA 1和HOXB 2纠正失调的修复机制,从而改善 COPD患者对呼吸道感染的免疫应答和肺功能。在具体目标1中,我们将确定 HOXA 1和HOXB 2在气道上皮再生中的作用,以及槲皮素是否能纠正 通过调节这些HOX基因在COPD中的失调修复机制。在具体目标2中,我们将研究 槲皮素诱导的HOXA 1和HOXB 2参与再生的分子机制 气道上皮在具体目标3中,我们将研究槲皮素诱导的HOXA 1和HOXB 2是否参与了 在限制对鼻病毒感染的过度先天免疫应答和预防肺部疾病进展方面 慢性阻塞性肺病最后,我们将证实槲皮素治疗是否减少COPD气道上皮重塑 与HOXA 1、HOXB 2表达相关。完成这些研究将提供 对气道上皮再生和槲皮素减少气道炎症的机制的重要见解 COPD中的上皮重塑。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Umadevi Sivanappa Sajjan其他文献

Umadevi Sivanappa Sajjan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Umadevi Sivanappa Sajjan', 18)}}的其他基金

Quercetin prevent airway epithelial remodeling and promote lung health in OPD
槲皮素可预防 OPD 患者气道上皮重塑并促进肺部健康
  • 批准号:
    10296535
  • 财政年份:
    2021
  • 资助金额:
    $ 45.13万
  • 项目类别:
Quercetin prevent airway epithelial remodeling and promote lung health in OPD
槲皮素可预防 OPD 患者气道上皮重塑并促进肺部健康
  • 批准号:
    10633252
  • 财政年份:
    2021
  • 资助金额:
    $ 45.13万
  • 项目类别:
Quercetin prevents progression of COPD lung disease by modulating Foxo3A activity
槲皮素通过调节 Foxo3A 活性预防 COPD 肺部疾病的进展
  • 批准号:
    8627791
  • 财政年份:
    2014
  • 资助金额:
    $ 45.13万
  • 项目类别:
Quercetin prevents progression of COPD lung disease by modulating Foxo3Aactivity
槲皮素通过调节 Foxo3A 活性预防 COPD 肺部疾病的进展
  • 批准号:
    9305694
  • 财政年份:
    2014
  • 资助金额:
    $ 45.13万
  • 项目类别:
Quercetin prevents progression of COPD lung disease by modulating Foxo3Aactivity
槲皮素通过调节 Foxo3A 活性预防 COPD 肺部疾病的进展
  • 批准号:
    9543962
  • 财政年份:
    2014
  • 资助金额:
    $ 45.13万
  • 项目类别:
Quercetin prevents progression of COPD lung disease by modulating Foxo3A activity
槲皮素通过调节 Foxo3A 活性预防 COPD 肺部疾病的进展
  • 批准号:
    8917098
  • 财政年份:
    2014
  • 资助金额:
    $ 45.13万
  • 项目类别:
Quercetin prevents progression of COPD lung disease by modulating Foxo3Aactivity
槲皮素通过调节 Foxo3A 活性预防 COPD 肺部疾病的进展
  • 批准号:
    9344531
  • 财政年份:
    2014
  • 资助金额:
    $ 45.13万
  • 项目类别:
Co-infections of rhinovirus and bacteria in chronic lung disorders
慢性肺部疾病中鼻病毒和细菌的双重感染
  • 批准号:
    7844968
  • 财政年份:
    2009
  • 资助金额:
    $ 45.13万
  • 项目类别:
Co-infections of rhinovirus and bacteria in chronic lung disorders
慢性肺部疾病中鼻病毒和细菌的双重感染
  • 批准号:
    7530219
  • 财政年份:
    2009
  • 资助金额:
    $ 45.13万
  • 项目类别:
Quercetin and Innate Immune Responses in COPD
槲皮素和慢性阻塞性肺病的先天免疫反应
  • 批准号:
    8103051
  • 财政年份:
    2008
  • 资助金额:
    $ 45.13万
  • 项目类别:

相似海外基金

EXposomic Profiling in Airway disease to uNravel Determinants of disease in Asthma (EXPAND-Asthma) Center
气道疾病暴露组分析以解开哮喘疾病的决定因素 (EXPAND-Asthma) 中心
  • 批准号:
    10744673
  • 财政年份:
    2023
  • 资助金额:
    $ 45.13万
  • 项目类别:
Bacteriophage as a predictive biomarker in chronic Pseudomonas airway disease
噬菌体作为慢性假单胞菌气道疾病的预测生物标志物
  • 批准号:
    10723956
  • 财政年份:
    2023
  • 资助金额:
    $ 45.13万
  • 项目类别:
Defining a gene expression signature of airway disease, COPD exacerbations, and response to treatment
定义气道疾病、COPD 恶化和治疗反应的基因表达特征
  • 批准号:
    10733573
  • 财政年份:
    2023
  • 资助金额:
    $ 45.13万
  • 项目类别:
Hydrogen Sulfide in Neonatal Airway Disease
新生儿气道疾病中的硫化氢
  • 批准号:
    10603293
  • 财政年份:
    2023
  • 资助金额:
    $ 45.13万
  • 项目类别:
Impact of Maternal Arsenic Exposure on Offspring's Epigenetic Reprogramming of Allergic Airway Disease
母亲砷暴露对后代过敏性气道疾病表观遗传重编程的影响
  • 批准号:
    10733607
  • 财政年份:
    2023
  • 资助金额:
    $ 45.13万
  • 项目类别:
The role of anaerobic microbiota in cystic fibrosis airway disease trajectory
厌氧微生物群在囊性纤维化气道疾病轨迹中的作用
  • 批准号:
    10716654
  • 财政年份:
    2023
  • 资助金额:
    $ 45.13万
  • 项目类别:
Immune Mediators of IL-22 Signaling Alter Allergic Airway Disease
IL-22 信号的免疫介质改变过敏性气道疾病
  • 批准号:
    10853347
  • 财政年份:
    2023
  • 资助金额:
    $ 45.13万
  • 项目类别:
Microbial adaptation of Pseudomonas lipid A structure in CF airway disease progress
假单胞菌脂质 A 结构在 CF 气道疾病进展中的微生物适应
  • 批准号:
    10722599
  • 财政年份:
    2023
  • 资助金额:
    $ 45.13万
  • 项目类别:
The role of anaerobic microbiota in cystic fibrosis airway disease trajectory
厌氧微生物群在囊性纤维化气道疾病轨迹中的作用
  • 批准号:
    10985906
  • 财政年份:
    2023
  • 资助金额:
    $ 45.13万
  • 项目类别:
Mentoring patient-oriented researchers in inflammatory airway disease
指导炎症性气道疾病领域以患者为中心的研究人员
  • 批准号:
    10657746
  • 财政年份:
    2022
  • 资助金额:
    $ 45.13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了